Los Angeles Lawyer | Chantix and Zyban (Suicidal Thoughts or Behavior)
Chantix and Zyban (Suicidal Thoughts or Behavior)
Chantix (varenicline tartrate), which is manufactured by Pfizer, Inc. and was approved by the FDA in 2006, is a smoking cessation drug that is intended to ease the side effects of nicotine withdrawal. Zyban (bupropion hydrochloride), which is manufactured by GlaxoSmithKline, was approved by the FDA in 1997 for use as a smoking cessation aid. The active ingredient in Zyban was originally marketed as Wellbutrin, an antidepressant.
Shortly after Chantix was approved, some individuals who started using this drug reported certain side effects, such as erratic behavior, suicidal thoughts, and depression. As a result, the FDA began a safety review of Chantix in 2007.
In July of 2009, the FDA mandated that a Black Box Warning, the FDA's most serious safety notice, be added to the labeling for Chantix and Zyban to highlight the risk of serious side effects, including changes in behavior, depression, hostility, and suicidal thoughts. The FDA received numerous reports of suicide and attempted suicide among patients taking Chantix and Zyban.
|< Prev||Next >|